Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DPX-SurMAGE
- Development stage
- Unknown
- Lead developer
- BioVaxys Technology Corporation
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
DPX-SurMAGE is an investigational cancer immunotherapy developed by IMV Inc. that leverages the proprietary DPX (DepoVax) delivery platform. This formulation incorporates HLA-restricted peptides from two tumor-associated antigens: Survivin (BIRC5) and Melanoma-associated antigen A9 (MAGE-A9). Survivin is an anti-apoptotic protein widely expressed in many cancers but rarely in normal adult tissues, making it an ideal target for immunotherapy. MAGE-A9 is a cancer-testis antigen frequently found in bladder cancer and other solid tumors. The DPX platform is a non-aqueous, lipid-in-oil delivery system designed to facilitate the uptake of antigens by antigen-presenting cells and provide a sustained release, thereby inducing a robust and long-lasting T-cell response. DPX-SurMAGE has been primarily investigated for the treatment of non-muscle invasive bladder cancer (NMIBC).
- Other names
- SurMAGE
02
Targets
MAGE-A9/HLA-A2 (Melanoma-associated antigen A9 peptide presented on HLA-A2)Sur1M2-HLA-A2 (Survivin-derived peptide–Major Histocompatibility Complex)
Beyond the preview
Go deeper on DPX-SurMAGE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DPX-SurMAGE.